Dr. Reddy's Laboratories

Dr. Reddy’s Laboratories Ltd.
Company typePublic
NSE: DRREDDY
BSE: 500124
NYSE: RDY
NSE NIFTY 50 constituent
ISININE089A01023
IndustryPharmaceuticals
Founded1984 (1984)
FounderAnji Reddy
HeadquartersHyderabad, Telangana, India
Area served
Worldwide
Key people
Products
Revenue 33,741 crore (US$4.0 billion) (2025)
7,657 crore (US$910 million) (2025)
5,930 crore (US$700 million) (2025)
Total assets 49,426 crore (US$5.8 billion) (2025)
Total equity 33,927 crore (US$4.0 billion) (2025)
Number of employees
24,832 (March 2023)
Websitewww.drreddys.com
Footnotes / references
Financials as of 31 March 2025.

Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration (FDA). By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.

By 2007, Dr. Reddy's had seven FDA plants producing active pharmaceutical ingredients in India and seven FDA-inspected and ISO 9001 (quality) and ISO 14001 (environmental management) certified plants making patient-ready medications five of them in India and two in the UK.